首站-论文投稿智能助手
典型文献
Gene mutation analysis and immune checkpoint therapy in head and neck squamous cell carcinoma
文献摘要:
Immune checkpoint inhibitors (ICI), represented by blocked programmed cell death-1 (PD-1), is a group of novel medicines for anti-tumor immunotherapy. It has been approved by the U.S. Food and Drug Administration (FDA) in recent years for relapsed or metastatic head and neck squamous cell carcinoma (HNSCC), and brings promising treatment prospects. However, the instability caused by tumor gene mutations significantly compromises the therapeutic effect of ICI. Therefore, the identification and analysis of HNSCC gene mutations can further guide and optimize the application of ICIs in HNSCC. In this study, we preliminarily described the clinical research progress of ICI therapy and the potential immune escape mechanism in HNSCC. An overview of complete HNSCC gene mutation results was generated from thebioinformatics study of TCGA database to further explain and analyze the relevant molecular mechanisms, which may aid in designing future personalized therapeutic strategies for HNSCC patients.
文献关键词:
作者姓名:
Hua Yang;Yuxue Wei;Gangli Liu
作者机构:
Department of Stomatology,The People's Hospital of Lanling County,Lanling 277700,China;School of Stomatology,Shandong University,Shandong Provincial Key Laboratory of Oral Tissue Regeneration,Jinan 250012,China
引用格式:
[1]Hua Yang;Yuxue Wei;Gangli Liu-.Gene mutation analysis and immune checkpoint therapy in head and neck squamous cell carcinoma)[J].肿瘤学与转化医学(英文),2022(01):36-42
A类:
thebioinformatics
B类:
Gene,analysis,immune,checkpoint,head,neck,squamous,cell,carcinoma,Immune,inhibitors,represented,by,blocked,programmed,death,group,novel,medicines,anti,tumor,immunotherapy,It,has,been,approved,Food,Drug,Administration,FDA,recent,years,relapsed,metastatic,HNSCC,brings,promising,treatment,prospects,However,instability,caused,mutations,significantly,compromises,therapeutic,effect,Therefore,identification,further,guide,optimize,application,ICIs,In,this,study,preliminarily,described,clinical,research,progress,potential,escape,An,overview,complete,results,was,generated,from,TCGA,database,explain,analyze,relevant,molecular,mechanisms,which,may,aid,designing,future,personalized,strategies,patients
AB值:
0.624124
相似文献
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
Yujiao Wang;Xi Jiao;Shuang Li;Huan Chen;Xin Wei;Chang Liu;Jifang Gong;Xiaotian Zhang;Xicheng Wang;Zhi Peng;Changsong Qi;Zhenghang Wang;Yanni Wang;Na Zhuo;Jianling Zou;Henghui Zhang;Jian Li;Lin Shen;Zhihao Lu-Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Gastric&Colorectal Surgery,The First Hospital of Jilin University,Changchun 130021,China;Genecast Precision Medicine Technology Institute,Beijing 100192,China;Life Sciences Institute,Zhejiang University,Hangzhou 310058,China;Institute of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis
Levy Dylan A.;Patel Jaimin J.;Nguyen Shaun A.;Jungbauer W. Nicholas;Neskey David M.;Cohen Ezra E. W.;Paulos Chrystal M.;Kaczmar John A.;Knochelmann Hannah M.;Day Terry A.-Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA;Department of Cell and Molecular Pharmacology and Developmental Therapeutics, Medical University of South Carolina, Charleston, South Carolina, USA;Department of Medicine, Division of Hematology-Oncology, University of California, San Diego, La Jolla, California, USA;Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA;Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA;Division of Hematology & Oncology, Medical University of South Carolina, Charleston, South Carolina, USA
A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patients
Taylor Janielle K.-A.;Mady Leila J.;Baddour Khalil;Iheagwara Uzoma K.;Zhai Shuyan;Ohr James P.;Zandberg Daniel P.;Gorantla Vikram C.;Ferris Robert L.;Kim Seungwon;Duvvuri Umamaheswar;Kubik Mark W.;Sridharan Shaum;Johnson Jonas T.;Holeva Karen D.;Quinn Annette E.;Clump David A.-School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA;Department of Otolaryngology—Head and Neck Surgery, UPMC, Pittsburgh, Pennsylvania, USA;UPMC Department of Radiation Oncology, UPMC, Pittsburgh, Pennsylvania, USA;Biostatistics, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA;Department of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA;Department of Immunology, UPMC, Pittsburgh, Pennsylvania, USA;Department of Plastic and Reconstructive Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Yang Liu;Ning Zhang;Cuicui Xie;Yale Jiang;Yunhe Qin;Liyun Zhou;Yi Fan;Lianjie Ren;Chen Yin;Huan Yang;Wei Xie;Qing Zhai;Guanqiao Li;Hongzhuan Chen;Xiaoyuan Chen-Tsinghua Clinical Research Institute(TCRI),School of Medicine,Tsinghua University,Beijing 100084,China;Center for Drug Evaluation,National Medical Products Administration,Beijing 100038,China;Pharmcube(Beijing)Co.,Ltd.,Beijing 100102,China;Department of Clinical Pharmacy,Cancer Hospital of Fudan University,Shanghai 200032,China;Vanke School of Public Health,Tsinghua University,Beijing 100084,China;Shanghai Collaborative Innovation Center for Translational Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Office of Clinical Trial Institute,Beijing Tsinghua Changgung Hospital,Beijing 102218,China
Stratifin promotes renal dysfunction in ischemic and nephrotoxic AKI mouse models via enhancing RIPK3-mediated necroptosis
Fang Wang;Jia-nan Wang;Xiao-yan He;Xiao-guo Suo;Chao Li;Wei-jian Ni;Yu-ting Cai;Yuan He;Xin-yun Fang;Yu-hang Dong;Tian Xing;Ya-ru Yang;Feng Zhang;Xiang Zhong;Hong-mei Zang;Ming-ming Liu;Jun Li;Xiao-ming Meng;Juan Jin-Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,School of Pharmacy,Anhui Medical University,The Key Laboratory of Anti-inflammatory of Immune Medicines,Ministry of Education,Hefei 230032,China;Department of Pharmacy,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Hospital of Stomatology,Anhui Medical University,Key Laboratory of Oral Diseases Research of Anhui Province,Hefei 230032,China;Department of Pharmacy,Changzheng Hospital,Naval Medical University,Shanghai 200003,China;Department of Nephrology,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。